Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Intracerebral hemorrhage is the least treatable form of stroke. We performed this phase 3 trial to confirm a previous study in which recombinant activated factor VII (rFVIIa) reduced growth of the hematoma and improved survival and functional outcomes. METHODS: We randomly assigned 841 patients with intracerebral hemorrhage to receive placebo (268 patients), 20 microg of rFVIIa per kilogram of body weight (276 patients), or 80 microg of rFVIIa per kilogram (297 patients) within 4 hours after the onset of stroke. The primary end point was poor outcome, defined as severe disability or death according to the modified Rankin scale 90 days after the stroke. RESULTS: Treatment with 80 microg of rFVIIa per kilogram resulted in a significant reduction in growth in volume of the hemorrhage. The mean estimated increase in volume of the intracerebral hemorrhage at 24 hours was 26% in the placebo group, as compared with 18% in the group receiving 20 microg of rFVIIa per kilogram (P=0.09) and 11% in the group receiving 80 microg (P<0.001). The growth in volume of intracerebral hemorrhage was reduced by 2.6 ml (95% confidence interval [CI], -0.3 to 5.5; P=0.08) in the group receiving 20 microg of rFVIIa per kilogram and by 3.8 ml (95% CI, 0.9 to 6.7; P=0.009) in the group receiving 80 microg, as compared with the placebo group. Despite this reduction in bleeding, there was no significant difference among the three groups in the proportion of patients with poor clinical outcome (24% in the placebo group, 26% in the group receiving 20 microg of rFVIIa per kilogram, and 29% in the group receiving 80 microg). The overall frequency of thromboembolic serious adverse events was similar in the three groups; however, arterial events were more frequent in the group receiving 80 microg of rFVIIa than in the placebo group (9% vs. 4%, P=0.04). CONCLUSIONS: Hemostatic therapy with rFVIIa reduced growth of the hematoma but did not improve survival or functional outcome after intracerebral hemorrhage. (ClinicalTrials.gov number, NCT00127283 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
(1965) · PubMed · Cited by 14,925
ASSESSMENT OF COMA AND IMPAIRED CONSCIOUSNESS
Teasdale, G., & Jennett, B. (1974) · The Lancet · doi:10.1016/s0140-6736(74)91639-0 · Cited by 13,215
Functional evaluation : Barthel index
Mahonery, F. I. (1965) · Medical Entomology and Zoology · Cited by 12,762
Interobserver agreement for the assessment of handicap in stroke patients
van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988) · Stroke · doi:10.1161/01.str.19.5.604 · Cited by 6,512
Measurements of acute cerebral infarction: a clinical examination scale.
Brott, T., Adams, H. P., Olinger, C. P., Marler, J. R., Barsan, W. G., Biller, J., Spilker, J., Holleran, R., Eberle, R., & Hertzberg, V (1989) · Stroke · doi:10.1161/01.str.20.7.864 · Cited by 5,911
WILSON, J. T. L., PETTIGREW, L. E. L., & TEASDALE, G. M. (1998) · Journal of Neurotrauma · doi:10.1089/neu.1998.15.573 · Cited by 2,386
The ICH Score: A Simple, Reliable Grading Scale for Intracerebral Hemorrhage
Hemphill, J. C., Bonovich, D. C., Besmertis, L., Manley, G. T., & Johnston, S. C. (2001) · Stroke · doi:10.1161/01.str.32.4.891 · Cited by 2,196
Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality.
Broderick, J. P., Brott, T. G., Duldner, J. E., Tomsick, T., & Huster, G. (1993) · Stroke · doi:10.1161/01.str.24.7.987 · Cited by 1,746
Self-citationEarly Hemorrhage Growth in Patients With Intracerebral Hemorrhage
Brott, T., Broderick, J., Kothari, R., Barsan, W., Tomsick, T., Sauerbeck, L., Spilker, J., Duldner, J., & Khoury, J. (1997) · Stroke · doi:10.1161/01.str.28.1.1 · Cited by 1,477
Self-citationHematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage
Davis, S. M., Broderick, J., Hennerici, M., Brun, N. C., Diringer, M. N., Mayer, S. A., Begtrup, K., & Steiner, T. (2006) · Neurology · doi:10.1212/01.wnl.0000208408.98482.99 · Cited by 1,168
Self-citation
Research works printed but not linked: 2
- Zimmerman RD, 2006, AJNR Am J Neuroradiol, 27, 666
- Mahoney FI, 1965, Md State Med J, 14, 61
Cited by
Items 301–400 of 1,000
Anti-Adrenergic Medications and Edema Development after Intracerebral Hemorrhage
Sansing, L. H., Messe, S. R., Cucchiara, B. L., Lyden, P. D., & Kasner, S. E. (2011) · Neurocritical Care · doi:10.1007/s12028-010-9498-z · Cited by 50
“Currently there is no specific treatment for ICH, as all large potential neuroprotectant, prothrombotic, and surgical trials have failed to show a convincing clinical benefit [1–4].”
BackgroundLuo, J., Chen, Y., Tang, G., Li, Z., Yang, X., Shang, X., Huang, T., Huang, G., Wang, L., Han, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.869846 · Cited by 54
“The inclusion criteria were as follows (1) age >18 years, (2) admission within 7 days of ICH onset, and (3) informed consent obtained and the retention of biological samples completed.”
BackgroundSurgical Management for Primary Intracerebral Hemorrhage
Morris, N. A., Simard, J. M., & Chaturvedi, S. (2024) · Neurology · doi:10.1212/wnl.0000000000209714 · Cited by 49
Koculym, A., Huynh, T. J., Jakubovic, R. Y., Zhang, L., & Aviv, R. I. (2012) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3338 · Cited by 49
Acute hypertensive response in patients with intracerebral hemorrhage pathophysiology and treatment
Qureshi, A. I., & Qureshi, M. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17725431 · Cited by 52
Disability-Adjusted Life-Years Associated With Intracerebral Hemorrhage and Secondary Injury
Haupenthal, D., Kuramatsu, J. B., Volbers, B., Sembill, J. A., Mrochen, A., Balk, S., Hoelter, P., Lücking, H., Engelhorn, T., Dörfler, A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.15859 · Cited by 55
Datar, S. V., & Rabinstein, A. A. (2014) · Neurologic Clinics · doi:10.1016/j.ncl.2014.07.006 · Cited by 49
Treatment of Acute Subdural Hematoma
Gerard, C. S., & Busl, K. M. (2013) · Current Treatment Options in Neurology · doi:10.1007/s11940-013-0275-0 · Cited by 48
Matsushita, H., Hijioka, M., Hisatsune, A., Isohama, Y., Iwamoto, S., Terasawa, H., & Katsuki, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067691 · Cited by 50
“For example, administration of activated recombinant factor VII (fVIIa) that could halt enlargement of hematoma after ICH failed to produce significant effects on mortality rate and neurological dysfunctions of patients in the phase III fVIIa for Acute Hemorrhagic Stroke Treatment (FAST) trial [8].”
BackgroundRecombinant Factor VII Is Associated With Worse Survival in Complex Cardiac Surgical Patients
Alfirevic, A., Duncan, A. E., You, J., Lober, C., & Soltesz, E. G. (2014) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2014.04.126 · Cited by 48
The Neurocritical and Neurosurgical Care of Subdural Hematomas
Huang, K. T., Bi, W. L., Abd‐El‐Barr, M. M., Yan, S. C., Tafel, I. J., Dunn, I. F., & Gormley, W. B. (2015) · Neurocritical Care · doi:10.1007/s12028-015-0194-x · Cited by 48
“Although there was much initial excitement about the use of rFVIIa in the reversal of anticoagulation-related intracerebral hemorrhages, further studies showed that rFVIIa did not generate thrombin as effectively as PCCs and furthermore caused more thromboembolic events [103].”
BackgroundBurchell, S. R., Tang, J., & Zhang, J. H. (2017) · Current Drug Targets · doi:10.2174/1389450118666170329152305 · Cited by 52
Geriatric care in the surgical intensive care unit
Menaker, J. A., & Scalea, T. M. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181ec5697 · Cited by 54
“It rapidly and effectively treats mildto-moderate coagulopathy postinjury (116, 118).”
BackgroundManagement of Ruptured Brain Arteriovenous Malformations
Zacharia, B. E., Vaughan, K. A., Jacoby, A., Hickman, Z. L., Bodmer, D., & Connolly, E. S. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0257-9 · Cited by 49
Acosta, J., Leasure, A. C., Kuohn, L. R., Both, C. P., Petersen, N., Sansing, L. H., Matouk, C. C., Testai, F. D., Langefeld, C. D., Woo, D., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000004891 · Cited by 47
Self-citationSurgical Evacuation of Intracerebral Hemorrhage
Kellner, C. P., Schüpper, A. J., & Mocco, J. (2021) · Stroke · doi:10.1161/strokeaha.121.032238 · Cited by 47
Coagulopathy in trauma patients: what are the main influence factors?
Maani, C. V., DeSocio, P. A., & Holcomb, J. B. (2009) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0b013e32832922be · Cited by 47
High Serum Levels of Growth Factors Are Associated with Good Outcome in Intracerebral Hemorrhage
Sobrino, T., Arias, S., Rodríguez‐González, R., Brea, D., Silva, Y., de la Ossa, N. P., Agulla, J., Blanco, M., Pumar, J. M., Serena, J. L., et al. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.182 · Cited by 52
“There is no effective treatment for this disease so far, despite some clinical trials have been accomplished (Lyden et al, 2007; Mayer et al, 2008; Mendelow et al, 2005).”
Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Lin, Y., Stanworth, S. J., Birchall, J. E., Doree, C. J., & Hyde, C. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005011.pub3 · Cited by 47
Leclerc, J. L., Lampert, A. S., Diller, M. A., Immergluck, J., & Doré, S. (2015) · ASN NEURO · doi:10.1177/1759091415578713 · Cited by 46
“Further, there are currently no effective therapies for the treatment of ICH, and the clinical management of patients focuses on supportive measures as surgical and medical management approaches have failed to improve outcomes (Sahni and Weinberger, 2007; Mayer et al., 2008; Rincon and Mayer, 2008; Crandall et al., 20…”
BackgroundIllanes, S., Zhou, W., Schwarting, S., Heiland, S., & Veltkamp, R. C. (2010) · Stroke · doi:10.1161/strokeaha.110.593541 · Cited by 49
Neuroprotective Therapies for Spontaneous Intracerebral Hemorrhage
Kearns, K. N., Ironside, N. T., Park, M. S., Worrall, B. B., Southerland, A. M., Chen, C., & Ding, D. (2021) · Neurocritical Care · doi:10.1007/s12028-021-01311-3 · Cited by 47
Metabolic Encephalopathies in the Critical Care Unit
Frontera, J. A. (2012) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000415431.07019.c2 · Cited by 51
“5% of patients.(17) Alternatives to rFVIIa include fresh frozen plasma (FFP) and unactivated prothrombin complex concentrates (PCCs), sometimes referred to as factor IX concentrates.”
BackgroundLi, M., Dai, X., Yu, X., Zou, W., Teng, W., Liu, P., Yu, X., An, Q., & Wen, X. (2021) · Journal of Molecular Neuroscience · doi:10.1007/s12031-021-01890-y · Cited by 50
Treatment of acute stroke: an update
Mikulík, R., & Wahlgren, N. G. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12387 · Cited by 50
Morotti, A., Jessel, M. J., Brouwers, H. B., Falcone, G. J., Schwab, K. M., Ayres, A. M., Vashkevich, A., Anderson, C. D., Viswanathan, A., Greenberg, S. M., et al. (2016) · Neurocritical Care · doi:10.1007/s12028-016-0241-2 · Cited by 47
Albaladejo, P., Pernod, G., Godiér, A., de Maistre, E., Rosencher, N., Mas, J., Fontana, P., Samama, C. M., Steib, A., Schlumberger, S., et al. (2018) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2018.04.009 · Cited by 53
“The studies that have tested the hypothesis of an improvement in the prognosis of these patients by the administration of rFVIIa [33,34] have responded negatively to this question.”
Miyahara, M., Noda, R., Yamaguchi, S., Tamai, Y., Inoue, M., Okamoto, K., & Hara, T. (2018) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2018.05.018 · Cited by 45
Glyceryl Trinitrate for Acute Intracerebral Hemorrhage
Krishnan, K., Scutt, P., Woodhouse, L. J., Adami, A., Becker, J., Berge, E., Cala, L., Casado, A. M., Caso, V., Chen, C., et al. (2015) · Stroke · doi:10.1161/strokeaha.115.010368 · Cited by 45
Hardy, J., Bélisle, S. J., & der Linden, P. V. (2008) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2008.05.013 · Cited by 46
Lin, Y., Moltzan, C., & Anderson, D. R. (2012) · Transfusion Medicine · doi:10.1111/j.1365-3148.2012.01164.x · Cited by 44
“No single trial showed a mortality benefit with the exception of the phase 2 RCT in ICH where mortality was a secondary outcome (Mayer et al., 2005a); the larger phase 3 RCT in ICH powered to detect a mortality difference was negative (Mayer et al., 2008).”
BackgroundResultInfluentialCha, B. G., Jeong, H., Kang, D., Nam, M.-J., Kim, C. K., Kim, D. Y., Choi, I.-Y., Ki, S., Kim, S. I., Han, J. H., et al. (2017) · Nano Research · doi:10.1007/s12274-017-1924-5 · Cited by 45
Early Rate of Contrast Extravasation in Patients with Intracerebral Hemorrhage
d’Esterre, C. D., Chia, T. L., Jairath, A., Lee, T. Y., Symons, S. P., & Aviv, R. I. (2011) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2669 · Cited by 43
Sheth, K. N., Cushing, T. A., Wendell, L., Lev, M. H., Romero, J. M., Schwab, K. M., Smith, E. E., Greenberg, S. M., Rosand, J. M., & Goldstein, J. N. (2009) · Neurocritical Care · doi:10.1007/s12028-009-9296-7 · Cited by 43
“Due to its strong association with poor clinical outcome, hematoma volume has also been used as an endpoint in clinical trials [6, 20].”
MethodAlavi, S., Jalalvand, M., Assadollahi, V., Tabibian, S., & Dorgalaleh, A. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1604109 · Cited by 43
Minimally invasive treatment for intracerebral hemorrhage
Abdu, E., Hanley, D. F., & Newell, D. W. (2012) · Neurosurgical FOCUS · doi:10.3171/2012.1.focus11362 · Cited by 47
Horstmann, S., Rizos, T., Lauseker, M., Möhlenbruch, M. A., Jenetzky, E., Hacke, W., Steiner, T., & Veltkamp, R. C. (2013) · Journal of Neurology · doi:10.1007/s00415-013-6939-6 · Cited by 46
“8 %) in our cohort compared to previous case series and clinical trials (range 20 to 32 %) [6, 13, 23, 24].”
ResultSelf-citationNanomedicine: An Emerging Novel Therapeutic Strategy for Hemorrhagic Stroke
Xu, Y., Chen, A., Jiehong, W., Wan, Y., You, M., Gu, X., Guo, H., Tan, S., He, Q., & Hu, B. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s357598 · Cited by 45
“Nevertheless, one Phase III randomized trial found no clinical benefit of hemostatic therapy in patients without coagulation disorder.(6) Therefore, current hemostasis should focus on patients with coagulopathy.”
Abulhasan, Y. B., Teitelbaum, J. S., Al-Ramadhani, K., Morrison, K. T., & Angle, M. R. (2023) · Neurology · doi:10.1212/wnl.0000000000207132 · Cited by 47
“Vasopressors 4 (8) 5 (5) 14 (15) 16 (24) 3 (21) —”
Nishijima, D. K., Dager, W. E., Schrot, R. J., & Holmes, J. F. (2010) · Academic Emergency Medicine · doi:10.1111/j.1553-2712.2010.00666.x · Cited by 42
Insertion of Intracranial Pressure Monitors in Fulminant Hepatic Failure Patients
Le, T. V., Rumbak, M. J., Liu, S. S., Alsina, A. E., van Loveren, H., & Agazzi, S. (2010) · Neurosurgery · doi:10.1227/01.neu.0000365517.52586.a2 · Cited by 42
Voils, S. A., Holder, M. C., Premraj, S., Catlin, J. R., & Allen, B. R. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.07.023 · Cited by 45
“Administration of recombinant factor VII, activated has been shown to increase the risk of thromboembolic events in a dose-related manner [10].”
BackgroundKrishnan, K., Mukhtar, S. F., Lingard, J., Houlton, A. E., Walker, E., Jones, T., Sprigg, N., Cala, L., Becker, J., Dineen, R. A., et al. (2015) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-309845 · Cited by 42
Tranexamic Acid in Cerebral Hemorrhage: A Meta-Analysis and Systematic Review
Hu, W., Xin, Y., Chen, X., Song, Z., He, Z., & Zhao, Y. (2019) · CNS Drugs · doi:10.1007/s40263-019-00608-4 · Cited by 46
Evidence-Based Treatment of Chronic Subdural Hematoma
Soleman, J., Taussky, P., Fandino, J., & Muroi, C. (2014) · InTech eBooks · doi:10.5772/57336 · Cited by 42
“The role of rFVIIa remains unclear, due to the known and relative frequent side-effects, such as deep vein thrombosis and pulmonary embolism, and high costs of this new drug [104, 105, 110].”
Recombinant Human Factor VIIa for Alveolar Hemorrhage Following Allogeneic Stem Cell Transplantation
Elinoff, J. M., Bağcı, U., Moriyama, B., Dreiling, J. L., Foster, B. H., Gormley, N. J., Salit, R. B., Cai, R., Sun, J., Beri, A., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.03.015 · Cited by 41
“Although rFVIIa was originally approved in the United States for use in patients with hemophilia and inhibitors to factors VIII or IX [18], off-label indications account for the vast majority of its use [19-25].”
Efficacy of Chitosan-Based Dressing for Control of Bleeding in Excisional Wounds.
Stricker-Krongrad, A.-H., Alikhassy, Z., Matsangos, N., Sebastian, R., Marti, G. P., Lay, F., & Harmon, J. W. (2018) · Europe PMC (PubMed Central) · Cited by 41
Mengel, A., Stefanou, M., Hadaschik, K. A., Wolf, M., Stadler, V., Poli, K., Lindig, T. M., Ernemann, U., Grimm, F., Tatagiba, M. S., et al. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004348 · Cited by 41
Clinical practice guidelines in intracerebral haemorrhage
Rodríguez‐Yáñez, M., Castellanos, M., Freijo, M. M., Fernández, J. C. L., Martí‐Fábregas, J., Nombela, F., Simal, P., Castillo, J., Díez‐Tejedor, E., Fuentes, B., et al. (2013) · Neurología (English Edition) · doi:10.1016/j.nrleng.2011.03.011 · Cited by 47
Lei, B., Sheng, H., Wang, H., Lascola, C. D., Warner, D. S., Laskowitz, D. T., & James, M. L. (2014) · Journal of Visualized Experiments · doi:10.3791/51439 · Cited by 43
Modeling Intracerebral Hemorrhage Growth and Response to Anticoagulation
Greenberg, C. H., Frosch, M. P., Goldstein, J. N., Rosand, J. M., & Greenberg, S. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048458 · Cited by 41
“Time-dependent decay of rupture, conversely, would be expected to depend on hemostatic factors such as the coagulation cascade, another observed determinant of hemorrhage volume [22,23].”
BackgroundIntracranial hemorrhage in cancer patients treated with anticoagulation
Weinstock, M. J., Uhlmann, E. J., & Zwicker, J. I. (2016) · Thrombosis Research · doi:10.1016/s0049-3848(16)30100-1 · Cited by 42
West, K. L., Adamson, C., & Hoffman, M. (2010) · Journal of neurosurgery · doi:10.3171/2010.7.jns091857 · Cited by 40
Robinson, M. T., Rabinstein, A. A., Meschia, J. F., & Freeman, W. D. (2010) · Stroke · doi:10.1161/strokeaha.110.581538 · Cited by 40
Therapies for Hemorrhagic Transformation in Acute Ischemic Stroke
Stone, J. A., Willey, J. Z., Keyrouz, S. G., Butera, J. N., McTaggart, R., Cutting, S., Silver, B., Thompson, B., Furie, K. L., & Yaghi, S. R. (2017) · Current Treatment Options in Neurology · doi:10.1007/s11940-017-0438-5 · Cited by 41
A Fate Worse Than Death: Prognostication of Devastating Brain Injury
Pratt, A. K., Chang, J. J., & Sederstrom, N. (2019) · Critical Care Medicine · doi:10.1097/ccm.0000000000003647 · Cited by 40
Kim, S., Kim, Y. E., Hong, S., Kim, K., Sung, D. K., Lee, Y., Park, W. S., Chang, Y. S., & Song, M. (2019) · Glia · doi:10.1002/glia.23712 · Cited by 42
“2020;68:178–192.wileyonlinelibrary.com/journal/glia the acute inflammation after the bleeding, may be associated with better prognosis in some cases (Mayer et al., 2008;Mazzola et al., 2014).”
BackgroundTelestroke 10 Years Later – ‘Telestroke 2.0’
Switzer, J. A., Levine, S. R., & Hess, D. C. (2009) · Cerebrovascular Diseases · doi:10.1159/000229550 · Cited by 40
“Public education is still inadequate for many Americans to understand that stroke is an emergency and their need to call 911 is immediate. In addition, the recent negative results of phase III clinical trials (SAINT II, DIAS II and FAST) in acute stroke mean that the immediate pipeline for complementary or additional…”
BackgroundLogan, A. C., & Goodnough, L. T. (2010) · Hematology · doi:10.1182/asheducation-2010.1.153 · Cited by 39
Thrall, J. H. (2016) · Radiology · doi:10.1148/radiol.2016160293 · Cited by 42
“In the original clinical trial of factor VII in the treatment of intracerebral hemorrhage (33), the drug was given number of analytic approaches, including the use of tissue texture analysis and deep learning systems, to look for associations between the quantitative phenotypic features in cancer images and genomic fe…”
BackgroundHall, A., Weaver, B. W., Liotta, E. M., Maas, M. B., Faigle, R., Mroczek, D. K., & Naidech, A. M. (2020) · Neurocritical Care · doi:10.1007/s12028-020-00982-8 · Cited by 42
S2k-Leitlinie: Behandlung von spontanen intrazerebralen Blutungen
Steiner, T., & Unterberg, A. W. (2021) · DGNeurologie · doi:10.1007/s42451-021-00381-z · Cited by 59
Self-citationThe Clinical Use of Prothrombin Complex Concentrate
Ferreira, J., & DeLosSantos, M. (2013) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2012.12.022 · Cited by 38
Qureshi, A. I., Palesch, Y. Y., Martin, R. H., Toyoda, Ḱ., Yamamoto, H., Wang, Y., Wang, Y., Hsu, C. Y., Yoon, B., Steiner, T., et al. (2014) · Europe PMC (PubMed Central) · Cited by 37
Self-citationNtaios, G., Bath, P. M., & Michel, P. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283355694 · Cited by 37
Medical management of intracerebral haemorrhage
Schreuder, F. H. B. M., Sato, S., Klijn, C. J. M., & Anderson, C. S. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-314386 · Cited by 42
Elkhatib, T. H. M., Shehta, N., & Bessar, A. A. (2019) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2019.04.038 · Cited by 38
Ironside, N. T., Chen, C., Mutasa, S., Sim, J., Ding, D., Marfatiah, S., Roh, D. J., Mukherjee, S., Johnston, K. C., Southerland, A. M., et al. (2020) · Stroke · doi:10.1161/strokeaha.119.026764 · Cited by 38
Self-citationCarvalho, M., Rodrigues, A., Gomes, M. E., Carrilho, A., Nunes, A. R., Órfão, R., Alves, Â., Aguiar, J., & Campos, M. (2014) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029614559773 · Cited by 42
Chan, S. L., Conell, C. A., Veerina, K. T., Rao, V. A., & Flint, A. C. (2015) · International Journal of Stroke · doi:10.1111/ijs.12507 · Cited by 36
Hemostasis in Intracranial Hemorrhage
Gulati, D., Dua, D., & Torbey, M. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00080 · Cited by 40
“Although both trials showed that rFVIIa was able to limit hematoma expansion, the phase III trial failed to demonstrate a benefit in functional outcome or mortality with significantly more thrombotic events as compared to placebo (9 versus 4%) (66, 67).”
BackgroundResultBrouwers, H. B., Battey, T. W. K., Musial, H. H., Ciura, V. A., Falcone, G. J., Ayres, A. M., Vashkevich, A., Schwab, K. M., Viswanathan, A., Anderson, C. D., et al. (2015) · Stroke · doi:10.1161/strokeaha.115.009659 · Cited by 35
Reyes‐Esteves, S., Nong, J., Glassman, P. M., Omo‐Lamai, S., Ohashi, S. N., Myerson, J. W., Zamora, M. E., Ma, X., Kasner, S. E., Sansing, L. H., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.037 · Cited by 35
Ciolino, J. D., Zhao, W., Martin, R. H., & Palesch, Y. Y. (2010) · Contemporary Clinical Trials · doi:10.1016/j.cct.2010.11.005 · Cited by 40
“The purpose of the FAST study was to confirm previous findings from another study in which recombinant activated factor VII (rFVIIa) reduced growth of hematoma and improved survival and functional outcomes following intracerebral hemorrhage.”
BackgroundResultInfluentialRisk of thromboembolic complications after intracerebral hemorrhage according to ethnicity
Christensen, M. C., Dawson, J., & Vincent, C. (2008) · Advances in Therapy · doi:10.1007/s12325-008-0092-0 · Cited by 35
DECOMPRESSIVE CRANIECTOMY FOR INTRACEREBRAL HEMORRHAGE
Marinković, I., Strbian, D., Pedrono, E., Vekovischeva, O. Y., Shekhar, S., Durukan, A., Korpi, E. R., Abo‐Ramadan, U., & Tatlisumak, T. (2009) · Neurosurgery · doi:10.1227/01.neu.0000351775.30702.a9 · Cited by 35
“Currently, no effective acute medical (9) or surgical (10) treatment exists, beyond general supportive measures.”
BackgroundOvesen, C., Havsteen, I. B., Rosenbaum, S., & Christensen, H. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2014.00186 · Cited by 35
“In the context of acute demonstration of ICH, the natural questions to be raised are: (1) what volume is the most predictive – the early volume with possible on-going hemorrhage or the final hematoma volume? (2) Is it safe to assume that a patient, who arrives early in the hospital and demonstrates a small hematoma vo…”
BackgroundMethodSpot and Diffuse Signs: Quantitative Markers of Intracranial Hematoma Expansion at Dual-Energy CT
Tan, C. O., Lam, S., Kuppens, D., Bergmans, R. H. J., Parameswaran, B. K., Forghani, R., Hu, R., Besheli, L. D., Goldstein, J. N., Thrall, J. H., et al. (2018) · Radiology · doi:10.1148/radiol.2018180322 · Cited by 35
Hill, M. D., & Muir, K. W. (2013) · Stroke · doi:10.1161/strokeaha.113.002790 · Cited by 35
Transfusion Therapy in Postpartum Hemorrhage
Padmanabhan, A., Schwartz, J. E., & Spitalnik, S. L. (2009) · Seminars in Perinatology · doi:10.1053/j.semperi.2009.01.002 · Cited by 40
Melmed, K. R., Lyden, P. D., Gellada, N. H., & Moheet, A. M. (2017) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2017.04.025 · Cited by 34
Detrimental Effects of Leptin on Intracerebral Hemorrhage via the STAT3 Signal Pathway
Kim, C. K., Ryu, W., Choi, I.-Y., Kim, Y. J., Rim, D., Kim, B. J., Jang, H., Yoon, B., & Lee, S. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.35 · Cited by 34
Sprigg, N., Flaherty, K., Appleton, J. P., Salman, R. A., Bereczki, D., Beridze, M., Ciccone, A., Collins, R., Dineen, R. A., Duley, L., et al. (2019) · Health Technology Assessment · doi:10.3310/hta23350 · Cited by 39
Han, J., Lee, J.-M., Koh, E. J., & Choi, H.-Y. (2014) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2014.56.4.303 · Cited by 33
Microglia Phenotype and Intracerebral Hemorrhage: A Balance of Yin and Yang
Bi, R., Fang, Z. H., You, M., He, Q., & Hu, B. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.765205 · Cited by 35
Wang, S., Zhou, Y., Yang, B., Li, L., Yu, S., Chen, Y., Zhu, J., & Zhao, Y. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00237 · Cited by 36
Progesterone Improves Neurobehavioral Outcome in Models of Intracerebral Hemorrhage
Lei, B., Wang, H., Jeong, S., Hsieh, J. T., Majeed, M. A., Dawson, H. N., Sheng, H., Warner, D. S., & James, M. L. (2015) · Neuroendocrinology · doi:10.1159/000442204 · Cited by 32
Cheng, C., Cui, J. Z., Ji, X., & Yao, L. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0311 · Cited by 32
Qureshi, A. I., Foster, L. D., Lobanova, I., Huang, W., & Suárez, J. I. (2020) · Cerebrovascular Diseases · doi:10.1159/000506358 · Cited by 37
Treatment of intracerebral hemorrhage: From specific interventions to bundles of care
Parry‐Jones, A., Moullaali, T. J., & Ziai, W. (2020) · International Journal of Stroke · doi:10.1177/1747493020964663 · Cited by 37
“Similarly, the FAST trial of rFVIIa showed a reduction in hematoma expansion but no improvement in 90-day mRS as well as an increase in thromboembolic complications at the highest dose.(23) Further trials are either underway or planned, and targeting subgroups with the highest risk of hematoma expansion (e.”
MethodNeurological Management of Fulminant Hepatic Failure
Frontera, J. A., & Kalb, T. H. (2010) · Neurocritical Care · doi:10.1007/s12028-010-9470-y · Cited by 32
“In addition, the rate of arterial thrombotic events with rFVIIa is as high as 8.5% [34] .”
BackgroundInfluentialIntracerebral Hemorrhage Specific Intensity of Care Quality Metrics
Qureshi, A. I. (2010) · Neurocritical Care · doi:10.1007/s12028-010-9453-z · Cited by 37
James, R. F., Palys, V., Lomboy, J., Lamm, J. R., & Simon, S. D. (2013) · Neurosurgical FOCUS · doi:10.3171/2013.2.focus1328 · Cited by 31
Recombinant Factor VIIa to Manage Major Bleeding from Newer Parenteral Anticoagulants
Vavra, K. A., Lutz, M. F., & Smythe, M. A. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m447 · Cited by 31
Cusack, T. J., Carhuapoma, J. R., & Ziai, W. (2018) · Current Treatment Options in Neurology · doi:10.1007/s11940-018-0486-5 · Cited by 36
Strickland, B. A., Bakhsheshian, J., Emmanuel, B., Amar, A. P., Giannotta, S. L., Russin, J. J., & Mack, W. J. (2021) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2021.01.005 · Cited by 31
Desborough, M., Salman, R. A., Stanworth, S. J., Havard, D., Woodhouse, L. J., Craig, J., Krishnan, K., Brennan, P. M., Dineen, R. A., Coats, T., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00157-6 · Cited by 31
Antiplatelet Pretreatment does not Increase Hematoma Volume in Experimental Intracerebral Hemorrhage
Lauer, A., Schlunk, F., Cott, E. M. V., Steinmetz, H., Lo, E. H., & Foerch, C. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.22 · Cited by 31
“This time point was chosen as a frequently used end point in clinical and experimental studies of ICH (Foerch et al, 2008; Mayer et al, 2008).”
BackgroundMethodComputed Tomography Angiography of the Carotid and Cerebral Circulation
Almandoz, J. E. D., Romero, J. M., Pomerantz, S. R., & Lev, M. H. (2010) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2010.02.007 · Cited by 31
“able to reduce the morbidity and mortality of this disease.(59,60) However, accurate patient selection to target hemostatic therapy only to those patients who are actively bleeding at the time of presentation (and hence are most likely to benefit from hemostatic therapy) is imperative.”
BackgroundProvencio, J. J., da Silva, I. R. F., & Manno, E. M. (2013) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2013.03.002 · Cited by 33
Metadata
- Authors
- Mayer, S. A., Brun, N. C., Begtrup, K., Broderick, J., Davis, S., Diringer, M. N., Skolnick, B. E., & Steiner, T.
- Affiliations
- Columbia University Irving Medical Center (US)
- Novo Nordisk (Denmark) (DK)
- University of Cincinnati Medical Center (US)
- The Royal Melbourne Hospital (AU)
- Washington University in St. Louis (US)
- Heidelberg University (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-15
- Volume
- 358
- Issue
- 20
- Pages
- 2127-2137
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2142640478
- Cited by
- 1,255
- References
- 29
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 44 · 2023: 36 · 2022: 38 · 2021: 75 · 2020: 71 · 2019: 57 · 2018: 59 · 2017: 75 · 2016: 60 · 2015: 68 · 2014: 77 · 2013: 90 · 2012: 105
- FWCI
- 70.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Health Sciences › Medicine › Clinical Neurology › Intracranial Aneurysms: Treatment and Complications
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- recombinant factor VIIa, intracerebral hemorrhage, hematoma expansion, hemorrhagic stroke, thromboembolic adverse events, functional outcome, modified Rankin Scale, hemostatic therapy, dose comparison, arterial events, bleeding complications, arterial thrombosis, venous thromboembolism
- MeSH terms
- Adult, Aged, Aged, 80 and over, Cerebral Hemorrhage, Double-Blind Method, Female, Hematoma, Humans, Male, Middle Aged, Recombinant Proteins, Tomography, X-Ray Computed, Glasgow Coma Scale, Factor VIIa, Treatment Failure, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.